SEC Form 3 · accession 0001214659-18-005594
NEXIEN BIOPHARMA, INC. · NXEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Courtney Lynne Clark
Director
Period of report
Aug 10, 2018
Accepted (ET)
Aug 17, 2018 · 11:06 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001625288
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| common stock | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stock (right to buy)F1 | $0.38 | holding | — | — | — | — | Aug 10, 2025 | Common Stock | 100,000 | — | D |
Explanation of responses
- F112,500 options to vest quarterly over next 8 quarters beginning September 30, 2018